Guided Therapeutics, Inc.
GTHP
$0.1088
$0.00888.80%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.00K | 38.00K | 38.00K | 82.00K | 98.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.00K | 38.00K | 38.00K | 82.00K | 98.00K |
| Cost of Revenue | 5.00K | 18.00K | 22.00K | 55.00K | 62.00K |
| Gross Profit | 2.00K | 20.00K | 16.00K | 27.00K | 36.00K |
| SG&A Expenses | 1.58M | 867.80K | 967.80K | 1.98M | 2.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.12M | 1.36M | 1.42M | 2.31M | 2.81M |
| Operating Income | -2.11M | -1.32M | -1.38M | -2.23M | -2.72M |
| Income Before Tax | -2.42M | -2.15M | -2.17M | -3.02M | -3.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.42 | -2.15 | -2.17 | -3.02 | -3.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.42M | -2.15M | -2.17M | -3.02M | -3.49M |
| EBIT | -2.11M | -1.32M | -1.38M | -2.23M | -2.72M |
| EBITDA | -2.10M | -1.31M | -1.37M | -2.22M | -2.71M |
| EPS Basic | -0.05 | -0.04 | -0.04 | -0.06 | -0.07 |
| Normalized Basic EPS | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 |
| EPS Diluted | -0.05 | -0.04 | -0.05 | -0.06 | -0.07 |
| Normalized Diluted EPS | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 229.34M | 220.54M | 214.97M | 209.95M | 204.50M |
| Average Diluted Shares Outstanding | 229.34M | 220.54M | 214.97M | 209.95M | 204.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |